Screening drug-induced arrhythmia events using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays

Circulation

Volumn 128, Issue SUPPL.1, 2013, Pages

  Navarrete, Enrique G ^a,b,c   Liang, Ping ^a,b,c   Lan, Feng ^a,b,c   Sanchez Freire, Verónica ^a,b,c   Simmons, Chelsey ^b,d   Gong, Tingyu ^a,b,c   Sharma, Arun ^a   Burridge, Paul W ^a,b,c   Patlolla, Bhagat ^a,b   Lee, Andrew S ^a,b,c   Wu, Haodi ^a,b,c   Beygui, Ramin E ^a,b   Wu, Sean M ^a,b   Robbins, Robert C ^a,b   Bers, Donald M ^e   Wu, Joseph C ^a,b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Lorry I Lokey Stem Cell Research Bldg   (United States)

^d Stanford University   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arrhythmias cardiac; Genomics; Myocytes cardiac; Pharmacogenetics; Pharmacology; Stem cells

Indexed keywords

QUINIDINE; SOTALOL; CARDIOVASCULAR AGENT;

ARTICLE; HEART ARRHYTHMIA; HEART BEAT; HEART DEPOLARIZATION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN INDUCED PLURIPOTENT STEM CELL DERIVED CARDIOMYOCYTE; LOW IMPEDANCE MICROELECTRODE ARRAY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; ACTION POTENTIAL; ADOLESCENT; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG SCREENING; IMPEDANCE; MALE; MICROELECTRODE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PLURIPOTENT STEM CELL; PROCEDURES; TISSUE MICROARRAY;

ACTION POTENTIALS; ADOLESCENT; ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR AGENTS; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; ELECTRIC IMPEDANCE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MALE; MICROELECTRODES; MYOCYTES, CARDIAC; TISSUE ARRAY ANALYSIS;

EID: 84883791986     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.000570     Document Type: Article

References (66)

1. Braam SR, Tertoolen L, van de Stolpe A, Meyer T, Passier R, Mummery CL. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res. 2010;4:107-116.
2. Mandenius CF, Steel D, Noor F, Meyer T, Heinzle E, Asp J, Arain S, Kraushaar U, Bremer S, Class R, Sartipy P. Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-the-art bioanalytics: A review. J Appl Toxicol. 2011;31:191-205.
3. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: Recent advances. Curr Opin Cardiol. 2007;22:39-43.
4. Denning C, Anderson D. Cardiomyocytes from human embryonic stem cells as predictors of cardiotoxicity. Drug Discov Today Therap Strat. 2008;5:223-232.
5. Fermini B, Fossa AA. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov. 2003;2:439-447.
6. Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of druginduced torsade de pointes. Trends Pharmacol Sci. 2003;24:619-625.
7. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32-45.
8. Antzelevitch C, Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol. 2002;17:43-51.
9. Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. J Clin Invest. 2005;115:2025-2032.
10. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev. 2010;62:760-781.
11. Martin RL, McDermott JS, Salmen HJ, Palmatier J, Cox BF, Gintant GA. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: Influence of multi-channel block. J Cardiovasc Pharmacol. 2004;43:369-379.
12. Masumiya H, Saito M, Ito M, Matsuda T, Noguchi K, Iida-Tanaka N, Tanaka H, Shigenobu K. Lack of action potential-prolonging effect of terfenadine on rabbit myocardial tissue preparations. Biol Pharm Bull. 2004;27:131-135.
13. Peng S, Lacerda AE, Kirsch GE, Brown AM, Bruening-Wright A. The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. J Pharmacol Toxicol Methods. 2010;61:277-286.
14. Cheng HC, Incardona J. Models of torsades de pointes: Effects of FPL64176, DPI201106, dofetilide, and chromanol 293B in isolated rabbit and guinea pig hearts. J Pharmacol Toxicol Methods. 2009;60:174-184.
15. Kyrozis A, Reichling DB. Perforated-patch recording with gramicidin avoids artifactual changes in intracellular chloride concentration. J Neurosci Methods. 1995;57:27-35.
16. Belles B, Malécot CO, Hescheler J, Trautwein W. "Run-down" of the Ca current during long whole-cell recordings in guinea pig heart cells: Role of phosphorylation and intracellular calcium. Pflugers Arch. 1988;411:353-360.
17. Hao LY, Kameyama A, Kameyama M. A cytoplasmic factor, calpastatin and ATP together reverse run-down of Ca2+ channel activity in guinea-pig heart. J Physiol. 1999;514(pt 3):687-699.
18. Hao LY, Wang WY, Minobe E, Han DY, Xu JJ, Kameyama A, Kameyama M. The distinct roles of calmodulin and calmodulin kinase II in the reversal of run-down of L-type Ca(2+) channels in guinea-pig ventricular myocytes. J Pharmacol Sci. 2009;111:416-425.
19. Ebert AD, Liang P, Wu JC. Induced pluripotent stem cells as a disease modeling and drug screening platform. J Cardiovasc Pharmacol. 2012;60:408-416.
20. Mordwinkin NM, Burridge PW, Wu JC. A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards. J Cardiovasc Transl Res. 2013;6:22-30.
21. Ma J, Guo L, Fiene SJ, Anson BD, Thomson JA, Kamp TJ, Kolaja KL, Swanson BJ, January CT. High purity human-induced pluripotent stem cell-derived cardiomyocytes: Electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol. 2011;301:H2006-H2017.
22. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, Thomson JA, Kamp TJ. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009;104:e30-e41.
23. Burridge PW, Keller G, Gold JD, Wu JC. Production of de novo cardiomyocytes: Human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell. 2012;10:16-28.
24. Carvajal-Vergara X, Sevilla A, D'Souza SL, Ang YS, Schaniel C, Lee DF, Yang L, Kaplan AD, Adler ED, Rozov R, Ge Y, Cohen N, Edelmann LJ, Chang B, Waghray A, Su J, Pardo S, Lichtenbelt KD, Tartaglia M, Gelb BD, Lemischka IR. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature. 2010;465:808-812.
25. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, Feldman O, Gepstein A, Arbel G, Hammerman H, Boulos M, Gepstein L. Modelling the long QT syndrome with induced pluripotent stem cells. Nature. 2011;471:225-229.
26. Matsa E, Rajamohan D, Dick E, Young L, Mellor I, Staniforth A, Denning C. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J. 2011;32:952-962.
27. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flügel L, Dorn T, Goedel A, Höhnke C, Hofmann F, Seyfarth M, Sinnecker D, Schömig A, Laugwitz KL. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med. 2010;363:1397-1409.
28. Sun N, Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez OJ, Navarrete EG, Hu S, Wang L, Lee A, Pavlovic A, Lin S, Chen R, Hajjar RJ, Snyder MP, Dolmetsch RE, Butte MJ, Ashley EA, Longaker MT, Robbins RC, Wu JC. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med. 2012;4:130ra47.
29. Yazawa M, Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J, Dolmetsch RE. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature. 2011;471:230-234.
30. Liang P, Lan F, Lee AS, Gong T, Sanchez-Freire V, Wang Y, Diecke S, Sallam K, Knowles JW, Nguyen PK, Wang PJ, Bers DM, Robbins RC, Wu JC. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease specific patterns of cardiotoxicity. Circulation. 2013;127:1677-1691.
31. Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L, Han L, Yen M, Wang Y, Sun N, Abilez OJ, Hu S, Ebert AD, Navarrete EG, Simmons CS, Wheeler M, Pruitt B, Lewis R, Yamaguchi Y, Ashley EA, Bers DM, Robbins RC, Longaker MT, Wu JC. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell. 2013;12:101-113.
32. Caspi O, Itzhaki I, Kehat I, Gepstein A, Arbel G, Huber I, Satin J, Gepstein L. In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells Dev. 2009;18:161-172.
33. Yang L, Soonpaa MH, Adler ED, Roepke TK, Kattman SJ, Kennedy M, Henckaerts E, Bonham K, Abbott GW, Linden RM, Field LJ, Keller GM. Human cardiovascular progenitor cells develop from a KDR+ embryonicstem-cell-derived population. Nature. 2008;453:524-528.
34. Brandenburger M, Wenzel J, Bogdan R, Richardt D, Nguemo F, Reppel M, Hescheler J, Terlau H, Dendorfer A. Organotypic slice culture from human adult ventricular myocardium. Cardiovasc Res. 2012;93:50-59.
35. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart. 1920;7:353-370.
36. Patterson S, Agin M, Anziono R, Burgess T, Chuang-Stein C, Dmitrienko A, Ferber G, Geraldes M, Ghosh K, Menton R, Natarajan J, Offen W, Sound J, Smith B, Suresh R, Zariffa N, A PRM. Investigating druginduced qt and qtc prolongation in the clinic: A review of statistical design and analysis considerations: Report from the pharmaceutical research and manufacturers of america qt statistics expert team. Drug Inf J. 2005;39:243-265.
37. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A. 2000;97:12329-12333.
38. Fernandez D, Ghanta A, Kauffman GW, Sanguinetti MC. Physicochemical features of the HERG channel drug binding site. J Biol Chem. 2004;279:10120-10127.
39. Dausse E, Berthet M, Denjoy I, André-Fouet X, Cruaud C, Bennaceur M, Fauré S, Coumel P, Schwartz K, Guicheney P. A mutation in HERG associated with notched T waves in long QT syndrome. J Mol Cell Cardiol. 1996;28:1609-1615.
40. Shimizu W, Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation. 1997;96:2038-2047.
41. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-1022.
42. El-Sherif N, Caref EB, Chinushi M, Restivo M. Mechanism of arrhythmogenicity of the short-long cardiac sequence that precedes ventricular tachyarrhythmias in the long QT syndrome. J Am Coll Cardiol. 1999;33:1415-1423.
43. Lacerda AE, Kuryshev YA, Chen Y, Renganathan M, Eng H, Danthi SJ, Kramer JW, Yang T, Brown AM. Alfuzosin delays cardiac repolarization by a novel mechanism. J Pharmacol Exp Ther. 2008;324:427-433.
44. Satin J, Kehat I, Caspi O, Huber I, Arbel G, Itzhaki I, Magyar J, Schroder EA, Perlman I, Gepstein L. Mechanism of spontaneous excitability in human embryonic stem cell derived cardiomyocytes. J Physiol. 2004;559(pt 2):479-496.
45. Martin RL, McDermott JS, Salmen HJ, Palmatier J, Cox BF, Gintant GA. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: Influence of multi-channel block. J Cardiovasc Pharmacol. 2004;43:369-379.
46. Doss MX, Di Diego JM, Goodrow RJ, Wu Y, Cordeiro JM, Nesterenko VV, Barajas-Martínez H, Hu D, Urrutia J, Desai M, Treat JA, Sachinidis A, Antzelevitch C. Maximum diastolic potential of human induced pluripotent stem cell-derived cardiomyocytes depends critically on I(Kr). PLoS One. 2012;7:e40288.
47. Otsuji TG, Minami I, Kurose Y, Yamauchi K, Tada M, Nakatsuji N. Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: Qualitative effects on electrophysiological responses to drugs. Stem Cell Res. 2010;4:201-213.
48. Sartiani L, Bettiol E, Stillitano F, Mugelli A, Cerbai E, Jaconi ME. Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: A molecular and electrophysiological approach. Stem Cells. 2007;25:1136-1144.
49. Jonsson MK, Wang QD, Becker B. Impedance-based detection of beating rhythm and proarrhythmic effects of compounds on stem cell-derived cardiomyocytes. Assay Drug Dev Technol. 2011;9:589-599.
50. Guo L, Abrams RM, Babiarz JE, Cohen JD, Kameoka S, Sanders MJ, Chiao E, Kolaja KL. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci. 2011;123:281-289.
51. Abassi YA, Xi B, Li N, Ouyang W, Seiler A, Watzele M, Kettenhofen R, Bohlen H, Ehlich A, Kolossov E, Wang X, Xu X. Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment. Br J Pharmacol. 2012;165: 1424-1441.
52. January CT, Riddle JM. Early afterdepolarizations: Mechanism of induction and block. A role for L-type Ca2+ current. Circ Res. 1989;64:977-990.
53. January CT, Riddle JM, Salata JJ. A model for early afterdepolarizations: Induction with the Ca2+ channel agonist Bay K 8644. Circ Res. 1988;62:563-571.
54. Abi-Gerges N, Ji GJ, Lu ZJ, Fischmeister R, Hescheler J, Fleischmann BK. Functional expression and regulation of the hyperpolarization activated non-selective cation current in embryonic stem cell-derived cardiomyocytes. J Physiol. 2000;523(pt 2):377-389.
55. Roden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length. Circ Res. 1985;56:857-867.
56. Davidenko JM, Cohen L, Goodrow R, Antzelevitch C. Quinidine-induced action potential prolongation, early afterdepolarizations, and triggered activity in canine Purkinje fibers. Effects of stimulation rate, potassium, and magnesium. Circulation. 1989;79:674-686.
57. He JQ, Ma Y, Lee Y, Thomson JA, Kamp TJ. Human embryonic stem cells develop into multiple types of cardiac myocytes: Action potential characterization. Circ Res. 2003;93:32-39.
58. Jonsson MK, Duker G, Tropp C, Andersson B, Sartipy P, Vos MA, van Veen TA. Quantified proarrhythmic potential of selected human embryonic stem cell-derived cardiomyocytes. Stem Cell Res. 2010; 4:189-200.
59. Marchetto MC, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y, Chen G, Gage FH, Muotri AR. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell. 2010;143:527-539.
60. Liu H, Ye Z, Kim Y, Sharkis S, Jang YY. Generation of endodermderived human induced pluripotent stem cells from primary hepatocytes. Hepatology. 2010;51:1810-1819.
61. Taura D, Sone M, Homma K, Oyamada N, Takahashi K, Tamura N, Yamanaka S, Nakao K. Induction and isolation of vascular cells from human induced pluripotent stem cells-brief report. Arterioscler Thromb Vasc Biol. 2009;29:1100-1103.
62. Lee YK, Ng KM, Lai WH, Chan YC, Lau YM, Lian Q, Tse HF, Siu CW. Calcium homeostasis in human induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Rev. 2011;7:976-986.
63. Beqqali A, Kloots J, Ward-van Oostwaard D, Mummery C, Passier R. Genome-wide transcriptional profiling of human embryonic stem cells differentiating to cardiomyocytes. Stem Cells. 2006;24:1956-1967.
64. Narsinh K, Narsinh KH, Wu JC. Derivation of human induced pluripotent stem cells for cardiovascular disease modeling. Circ Res. 2011;108:1146-56.
65. Cao F, Wagner RA, Wilson KD, Xie X, Fu JD, Drukker M, Lee A, Li RA, Gambhir SS, Weissman IL, Robbins RC, Wu JC. Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. PLoS One. 2008;3:e3474.
66. Lee P, Klos M, Bollensdorff C, Hou L, Ewart P, Kamp TJ, Zhang J, Bizy A, Guerrero-Serna G, Kohl P, Jalife J, Herron TJ. Simultaneous voltage and calcium mapping of genetically purified human induced pluripotent stem cell-derived cardiac myocyte monolayers. Circ Res. 2012;110:1556-1563.